FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2

Ahmed Mostafa 1,*,†, Ahmed Kandeil 1,†, Yaseen A. M. M. Elshaier 2, Omnia Kutkat 1,*, Yassmin Moatasm 1, Adel A. Rashad 3, Mahmoud Shehata 1,*, Mokhtar R. Gomaa 1, Noura Mahrous 1, Sara H. Mahmoud 1, Mohamed GabAllah 1, Hisham Abbas 4,†, Ahmed El Taweel 1, Ahmed E. Kayed 1, Mina Nabil Kamel 1, Mohamed El Sayes 1, Dina B. Mahmoud 5, Rabeh El-Shesheny 1,*, Ghazi Kayali 6,7,* and Mohamed A. Ali 1,*,*.

1 Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; Ahmed.Kandeil@human-link.org(A.K); Omnia.Abdelaziz@human-link.org(O.K); Yassmin.Moatasm@human-link.org(Y.M); Mahmoud.Shehata@human-link.org(M.S); Mokhtar.Rizk@human-link.org(M.R.G); noura.mahrous1995@gmail.com(N.M); Sarah.Hussein@human-link.org(S.H.M); gaballah09@gmail.com(M.G); Ahmed.Nageh@human-link.org(A.E.T); Ahmed.Elsayed@human-link.org(A.E.K); minanabil56@yahoo.com(M.N.K); mohametdiaaelsayes@outlook.com(M.E.S); ra_eny@yahoo.com(R.E.-S).

2 Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt; yaseen.elsaier@fop.usc.edu.eg

3 Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, USA; aaa396@drexel.edu

4 Department of Microbiology and Immunology, Zagazig University, Zagazig 44519, Egypt; hishamabbas2008@gmail.com

5 Pharmaceutics Department, National Organization for Drug Control and Research, Giza 12654, Egypt; dina_bahaa2007@yahoo.com

6 Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA

7 Human Link, Baabda 1109, Lebanon

* Correspondence: ahmed_elsayed@daad-alumni.de(A.M.); ghazi@human-link.org(G.K); mohamedahmedali2004@yahoo.com(M.A.A.)

† Contributed equally to this work.

Received: 22 October 2020; Accepted: 1 December 2020; Published: 4 December 2020

Abstract: (1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystallized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active
(4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.

**Keywords:** SARS-CoV-2; COVID-19; antiviral; virtual screening; drug repurposing

---

### 1. Introduction

Coronaviruses (CoVs) with positive-sense single-stranded RNA genome of non-segmented nature are divided according to phylogenetic clustering into four genera (alpha-, beta-, gamma-, and delta-CoVs) within subfamily Coronavirinae and family Coronaviridae of the Nidovirales order. The Beta-CoVs, of the greatest clinical importance to humans, are further subclassified into four lineages [1].

For many years, two alpha-CoVs (HCoV-229E, HCoV-NL63) and two beta-CoVs (HCoV-OC43 and HCoV-HKU1) were known to be associated with a mild and self-limiting respiratory infection in humans, namely the common cold. This list of low pathogenic coronaviruses was recently expanded by the addition of two highly pathogenic human beta-CoVs, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 [2–4].

On 31 December 2019, a cluster of human infections in Wuhan city, Hubei province, China, of unknown etiology was reported to the World Health Organization (WHO) China Country Office. The infections were associated with elevated temperature, cough, shortness of breath, and pneumonia [5]. On 7 January 2020, the Chinese authorities attributed these respiratory infections to a new type of coronavirus. The new virus was designated firstly as 2019 novel coronavirus (2019-nCoV) and then Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), but the disease itself is known as coronavirus disease 2019 (COVID-19). A few weeks later, the COVID-19 was vastly reported in all provinces in China and later expanded to all continents. As of 8 September 2020, COVID-19 is responsible for >27 million confirmed human cases in >215 countries and territories, with approximately 900,000 human deaths, but the actual number of cases is much higher due to asymptomatic infections [6,7]. The Phylogenic analysis of the ancestor of SARS-CoV-2 showed that this novel virus is more similar to the 2003 SARS-CoV and that both belong to lineage B of Beta-CoVs [8].

Despite that a great effort is currently running in the direction of vaccine development and drug repurposing, most of the clinically used drugs to relieve COVID-19 symptoms were based on clinical observations rather than experimental validations. To rapidly define potential therapeutic options against SARS-CoV-2, testing existing Food and Drug Administration (FDA)-licensed drugs for efficacy against novel viral pathogens represents a practical approach for anti-CoV screening. This could expedite the recommendation and/or implementation of those FDA-approved drugs with effective anti-COVID-19 activity in the treatment protocol [9,10].

Concerns have been raised that steroidal and non-steroidal anti-inflammatory drugs (SAIDs and NSAIDs, respectively) may be associated with an increased risk of adverse events when used in patients with acute viral respiratory infections, including COVID-19 [11,12], however, no clear evidence of severe adverse effects in patients with COVID-19 were reported [13]. On the other hand, antibiotics are commonly prescribed for treating respiratory bacterial infections. Besides, they are prescribed in viral infections based on clinical antiviral observations or to combat potential secondary bacterial infection [14]. The improper use of antibiotics to combat the COVID-19 pandemic will strengthen bacterial resistance and ultimately lead to more deaths during the crisis and beyond [15]. In this study, we investigated the impact of commonly prescribed anti-asthmatics, antibiotics, SAIDs, and NSAIDs, on the replication efficiency of SARS-CoV-2 virus in vitro in cell culture.
2. Results

2.1. Antiviral Activity Screening for Commonly Prescribed FDA-Approved Analgesics, Antipyretics, Anti-Inflammatory Drugs, and Antibiotics

The selected FDA-approved drugs were chosen (Table 1) based on different criteria, including their common prescription in Influenza-like illness (ILI) and in quarantine (clinic and self-isolation programs), and their application in treatment protocols for COVID-19 due to an observed improvement in illness-associated symptoms. The majority of the selected FDA-approved drugs are over the counter (OTC) medicines in developing countries, meaning that they can be bought without a prescription. This eases their intensive consumption by the public to treat mild to moderate ILI infections. Little is known about the antiviral activity of these predefined libraries of FDA-approved drugs.

2.2. Cytotoxicity and Antiviral Activity of Selected FDA-Approved Drugs

To identify the proper concentrations to define the antiviral activity of the selected drugs, half maximal cytotoxic concentration “CC50” was calculated by MTT assay for each individual drug (Table 1, Supplementary Figures S1 and S2). The antiviral screening revealed that a large number of the tested FDA-approved drugs exhibited a promising in vitro activity against NRC-03-nhCoV and have promising antiviral activities with a high selectivity index (≥100) for antiviral activity relative to cellular toxicity (Table 1, Figure 1, Supplementary Figures S3 and S4).
**Table 1.** Antiviral activity of anti-microbial and anti-inflammatory FDA-approved drugs against NRC-03-nhCoV.

(A) Anti-microbial FDA-approved drugs

| FDA-approved drug               | Initial indication                        | CC\(_{50}\) (Vero-E6) | IC\(_{50}\) (NRC-03-nhCoV) | SI  |
|--------------------------------|------------------------------------------|-------------------------|-----------------------------|-----|
| Amikacin sulphate             | Aminoglycoside antibiotic                | 2456 µM                 | 16.81 µM                    | 146.10 |
| Azithromycin                   | Macrolide-type antibiotic               | 793 µM                  | 0.32 µM                     | 2478.13 |
| Amoxicillin                   | Penicillin-type antibiotic              | 614.57 µM               | 16.12 µM                    | 38.12 |
| Benzathine penicillin         | Long-acting penicillin antibiotic       | 728.2 µM                | 15.78 µM                    | 46.15 |
| Chloramphenicol               | Broad-spectrum bacteriostatic antibiotic | 33.92 µM                | 16.94 µM                    | 2.00 |
| Cefotaxime                    | Third-generation cephalosporin antibiotic| 3155 µM                 | 42.72 µM                    | 73.85 |
| Cephalexin                    | First-generation cephalosporin antibiotic| 522.95 µM              | 13.17 µM                    | 39.71 |
| Ceftriaxone                   | Third-generation cephalosporin antibiotic| 445.91 µM             | 16.34 µM                    | 27.63 |
| Cefoperazone                  | Third-generation cephalosporin antibiotic| 69.03 µM              | 12.36 µM                    | 5.58 |
| Ceftazidime                   | Third-generation cephalosporin antibiotic| 5554 µM               | 46.14 µM                    | 120.37 |
| Clindamycin                   | Lincosamide antibiotic                  | 436.45 µM               | 15.67 µM                    | 27.85 |
| Ciprofloxacin                 | Fluoroquinolone antibiotic              | 3516 µM                 | 61.62 µM                    | 57.06 |
| Doxycycline                   | Tetracycline antibiotic                 | 636.1 µM                | 5.1 µM                      | 124.73 |
| Flucloxacillin                | Narrow-spectrum penicillin-type antibiotic| 966.23 µM            | 157.78 µM                   | 6.12 |
| Levofoxacin                   | Fluoroquinolone antibiotic              | 2156 µM                 | 13.84 µM                    | 155.78 |
| Linezolid                     | Narrow-spectrum oxazolidinone antibiotic | 816.5 µM              | 16.3 µM                     | 50.1 |
| Moxifloxacin                  | Fluoroquinolone antibiotic              | 2242 µM                 | 12.23 µM                    | 183.32 |
| Nitrofurantoin                | Narrow-spectrum antibiotic              | 599.113 µM             | 16.22 µM                    | 36.94 |
| Neomycin                      | Aminoglycoside antibiotic               | 833.1 µM                | 18.12 µM                    | 45.98 |
| Niclosamide                   | Anthelminthic and antibacterial drug     | 204.61 µM              | 0.16 µM                     | 1278.81 |
| Nitazoxamide                  | Broad-spectrum anti-infective drug      | 665.15 µM              | 1.29 µM                     | 515.62 |
| Nystatin                      | Antifungal medication                   | 182.64 µM              | 160.85 µM                   | 1.14 |

(B) Analgesics and antipyretics

| FDA-approved drug              | Initial indication                        | CC\(_{50}\) (Vero-E6) | IC\(_{50}\) (NRC-03-nhCoV) | SI  |
|--------------------------------|------------------------------------------|-------------------------|-----------------------------|-----|
| Acetyl Salicylic acid “Aspirin”| Anti-inflammatory and antipyretic        | 1255 µM                 | 12.16 µM                    | 103.21 |
| Paracetamol                    | Analgesic and antipyretic                | 4980 µM                 | ≥IC\(_{50}\)                | <1  |
| Celecoxib                      | Nonsteroidal anti-inflammatory drug (NSAID)| 140.37 µM          | 13.02 µM                    | 10.78 |
| Ciclesonide                    | Glucocorticoid used to treat asthma and rhinitis| 119.5 µM            | 4.2 µM                      | 28.73 |
| Chlorpheniramine maleate       | Antihistamine used to treat allergic rhinitis| 465.65 µM          | 3.6 µM                      | 129.35 |
| Dexamethasone                  | Anti-inflammatory corticosteroid medication| 1901 µM              | 122.55 µM                   | 15.51 |
Table 1. Cont.

(B) Analgesics and antipyretics

| FDA-approved drug         | Initial indication                                   | CC<sub>50</sub> (Vero-E6) | IC<sub>50</sub> (NRC-03-nhCoV) | SI    |
|---------------------------|-------------------------------------------------------|-----------------------------|-------------------------------|-------|
| Diclofenac sodium         | Nonsteroidal anti-inflammatory drug (NSAID)           | 138.31 µM                   | 96.24 µM                      | 1.44  |
| Fluticasone Propionate    | Synthetic glucocorticoid to treat asthma and COPD     | 32.04 µM                    | 1.71 µM                       | 18.74 |
| Formoterol Fumarate       | Long-acting bronchodilator                            | 568.63 µM                   | 71.8 µM                       | 7.92  |
| Hydrocortisone            | Anti-inflammatory glucocorticoid                      | 614 µM                      | 7.1 µM                        | 87.10 |
| Indomethacin              | Nonsteroidal anti-inflammatory drug                   | 671.7 µM                    | 8.51 µM                       | 78.93 |
| Ibuprofen                 | Nonsteroidal anti-inflammatory drug                   | 1166 µM                     | 88.71 µM                      | 13.14 |
| Ketoprofen                | Nonsteroidal anti-inflammatory drug                   | 32.04 µM                    | 1.71 µM                       | 18.74 |
| Ketorolac Tromethamine    | Nonsteroidal anti-inflammatory drug                   | 822.62 µM                   | 21.5 µM                       | 38.31 |
| Metamizole sodium         | Analgesic and antipyretic                             | 2042 µM                     | 153.42 µM                     | 13.31 |
| Montelukast               | Leukotriene receptor antagonist to treat asthma       | 9.86 µM                     | 2.7 µM                        | 3.65  |
| Meloxicam                 | Nonsteroidal anti-inflammatory drug                   | 262.16 µM                   | 12.4 µM                       | 21.21 |
| Methylprednisolone        | Glucocorticoid anti-inflammatory medication           | 3344 µM                     | 90.44 µM                      | 36.97 |
| Naphazoline               | Decongestant                                          | 636.1 µM                    | 9.52 µM                       | 66.82 |
| Piroxicam                 | Nonsteroidal anti-inflammatory drug                   | 1795 µM                     | 8.21 µM                       | 218.64|
| Salmeterol                | Long-acting bronchodilator                            | 4.1 µM                      | 1.5 µM                        | 2.73  |

Abbreviations: “CC<sub>50</sub>” half maximal cytotoxic concentration; “IC<sub>50</sub>” half maximal inhibitory concentration; “SI” Safety index; “COPD” Chronic obstructive pulmonary disease. Bold: FDA-approved drugs with high selectivity index (SI ≥ 100).
Figure 1. Dose-inhibition curves for anti-microbial and anti-inflammatory FDA-approved drugs with high selectivity indices against NRC-03-nhCoV. (a) Amikacin sulphate, Azithromycin, Ceftazidime, Doxycycline, Levofloxacin, Moxifloxacin, Niclosamide, and Nitazoxanide, (b) Aspirin, Chlorpheniramine maleate, and Piroxicam. Inhibitory concentration 50% (IC\textsubscript{50}) values were calculated using nonlinear regression analysis of GraphPad Prism software (version 5.01) by plotting log inhibitor versus normalized response (variable slope).
2.3. Mechanism of Anti-SARS-CoV-2 Activity for Promising FDA-Approved Drugs

The percent inhibition of various mechanisms of action are shown in Table 2. Interestingly, Azithromycin, Niclosamide, and Nitazoxanide have the least dual combinations of viral inhibitory effects on SARS-CoV-2 at different viral stages. Azithromycin has up to 51% virucidal effect, indicating that it acts directly on the virion and inactivates it. Additionally, it showed up to 31% inhibition at 1.3 µM concentration during the viral adsorption stage and negligible effect on viral replication. Niclosamide exhibited moderate virucidal effect with 37% viral inhibitory effect as well as 70% inhibitory effect on virus replication. A negligible reduction in viral inhibition was detected during application of viral adsorption mechanism. Nitazoxanide showed multiple inhibitory effects at the three stages but potency of its activity is mainly virucidal effect.

Table 2. Mechanisms of action of FDA-approved anti-microbial drugs with promising antiviral activity for repurposing against COVID-19.

| Name of Compound | Conc. (µM) | Mode of Action * | Viral Adsorption | Viral Replication | Virucidal |
|------------------|------------|------------------|------------------|-------------------|-----------|
| Azithromycin     | 1.3        |                  | 31%              | 4%                | 51%       |
|                  | 0.64       |                  | 27%              | 2%                | 51%       |
|                  | 0.322      |                  | 2%               | 0%                | 34%       |
|                  | 0.16       |                  | 0%               | 0%                | 12%       |
|                  | 10.4       |                  | 0%               | 70%               | 37%       |
| Niclosamide      | 5.2        |                  | 0%               | 68%               | 21%       |
|                  | 2.6        |                  | 0%               | 55%               | 21%       |
|                  | 1.302      |                  | 0%               | 23%               | 16%       |
|                  | 10.4       |                  | 11%              | Toxic             | 78%       |
| Nitazoxanide     | 5.2        |                  | 11%              | Toxic             | 75%       |
|                  | 2.6        |                  | 1%               | 40%               | 61%       |
|                  | 1.302      |                  | 0%               | 35%               | 39%       |

* The mechanism of action of the three compounds were done at concentrations higher than the half-maximal inhibitory effect "IC$_{50}$" to better resolve the mechanism of action.

2.4. Molecular Modeling and Virtual Screening Study

2.4.1. Molecular Docking Study

The X-ray crystal structure coordinates of SAR-CoV-2 main protease (M$_{\text{pro}}$) were retrieved from protein data bank (PDB) ID: 6yef [16] and 6lu7 [17], in addition to the retrieved receptor for S glycoprotein (PDB ID:6vsb [18]), with their co-crystallized bounded ligands α-ketoamide, N3, and ligand 1, respectively (Figure 2). The docking study was performed using the OpenEye software (EON 2.3.3.4: OpenEye Scientific Software, Santa Fe, NM, USA. http://www.eyesopen.com). For the validation of the docking study, the co-crystal-bound ligands were redocked. Both structures exhibited high similarity and overlaid each other, as reported previously [16].

Docking with M$_{\text{pro}}$ (PDB ID: 6lu7) of SARS-CoV-2

From the analysis of binding modes of Azithromycin, Niclosamide, and Nitazoxanide, as illustrated in Table 1, these drugs showed a correlation between their activity and their interaction with M$_{\text{pro}}$ (PDB ID: 6lu7). Azithromycin (basic drug) fully occupied the receptor domains with the formation of two hydrogen bonds (HBs) with GLU:166A and GLN:189A (Figure 3a). Both amino acids interacted with the co-crystallized ligand as reported. Both Niclosamide and Nitazoxanide occupied the active site without detection of HB (Figure 3b). However, the salicyloyl moiety of Nitazoxanide overlays with the P-nitroaniline moiety of Niclosamide towards the receptor domain with ASP:187A-GLN:189A peptide part. The other groups of both drugs adopted different poses: the phenolic part of Niclosamide oriented closely toward the GLU:166A, MET:165A, and HIS:164A peptide cleft, especially in chlorine
atoms and hydroxyl functionality. On the other hand, the thiazole ring adopted a position close to GLU:192A, LEU:176A, and VAL:186A cleft. This binding mode and pattern could explain the high activity of Niclosamide because of its capability to interact with the receptor via the most important key amino acids, especially GLU:166A and GLN:189A.

Figure 2. Chemical structure of ligands α-ketomaide and N3 for SARS-CoV-2 M(pro) (PDB ID: 6lu7, 6y2f), and Ligand 1 for SARS-CoV-2 spike glycoprotein (PDB ID: 6vsb).

Docking with Spike Glycoprotein (PDB ID: 6vsb)

Docking of targeted drugs towards spike glycoprotein (PDB ID: 6vsb [18]) displayed the strength of Nitazoxanide, Niclosamide, and Azithromycin (Table 3). The co-crystalized ligand showed multiple HBs as peptidomimetic drugs, especially amino acids: ASN:422A (two HBs), GLN:493A, SER:494A, and TyR:495A (Figure 4a,b) (as reported). Azithromycin was detected with formation of HB with LYS:417A, however, it adopted a position far from the key peptide GLN:493A-TyR:495A (Figure 4c). Nitazoxanide binds strongly with formation of HB with ASN:422A through the NH amidic of aminothiazole (Figure 4d), while Niclosamide promoted HB interaction toward the critical peptide moiety (as displayed from standard ligand) with GLN:493A through its phenolic OH group (Figure 4e). This different binding mode of HB formation will affect drugs’ metabolism and subsequently their activity against SARS-CoV-2.
Figure 3. Visual representation by volumetric image display and analysis (VIDA) of docking with M<sup>pro</sup> (PDB ID: 6lu7). (a) Azithromycin docked with the formation of two HBs (green color). (b) Niclosamide (grey color) and Nitazoxanide (thiazole ring with yellow-blue color) occupied the active site without detection of HB.
Table 3. Binding mode of most active drugs with their consensus score against spike glycoprotein and M\textsuperscript{pro}.

| Name of Compound | Spike Glycoprotein | Main Protease | Binding Interaction | Binding Interaction |
|------------------|-------------------|---------------|---------------------|---------------------|
|                  | 6v3b              | 6y2f          | 6lu7                |                     |
| Azithromycin     | 173               | 153           | 197                 | HBs with GLU:166A and GLN:189A. Fully occupied receptor domains with two terminal HBs formation. |
| Niclosamide      | 153               | 153           | 113                 | No HB formation. The phenolic moiety oriented deeply in the pocket domain. |
| Nitazoxanide     | 150               | 96            | 134                 | No HB formation. The salicyloyl moiety oriented deeply in the pocket domain. |

Abbreviations: HB (Hydrogen Bond); LYS (Lysine); GLU (Glutamic acid); GLN (Glutamine); ASN (Asparagine); MET (Methionine); A (Alanine).
Figure 4. Cont.
2.4.2. Ligand Efficiency (LE) and Ligand lipophilic Efficiency (LLE) Scores

During drug repositioning, a drug undergoes the complete scenario of the drug development process. The assessment of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties, especially the lipophilicity factor, is important in drug discovery and development. The affinity between the ligand and the target is a dominant parameter in drug discovery. Currently, validation of the molecular size, lipophilicity (cLogP), together with drugs’ activities (pIC$_{50}$) using various helpful parameters designated as “optimization measures”, is required.

Ligand efficiency (LE) is used to determine the competence of drugs through calculation of its binding affinity (in terms of binding energy or pIC$_{50}$) in relation to the number of heavy atoms in a molecule (number of non-hydrogen atoms (NHA)). LE analyses have practical utility in “lead optimization” towards a “drug-like candidate”, especially in a drug repurposing approach [19,20].

Figure 4. Visual representation by VIDA for docking with spike glycoprotein (PDB ID: 6vsb). (a) Standard ligand docked inside the receptor (HB in green color), (b) ligand inside the inner grid for validation, (c) Azithromycin docked peripherally, (d) Nitazoxanide docked with formation of weak HB (green color), and (e) Niclosamide docked with formation of strong HB (green color).
This tactic compares the affinity of drugs corrected for their size instead of considering the effectiveness or binding affinity of the whole structure. It is calculated as demonstrated in the following equations:

\[
LE = \frac{\Delta G}{NHA} \text{ or } LE = \frac{(\text{pIC}_{50} \times 1.37)}{NHA}
\]

where \( \Delta G \) = Gibb’s free energy, \( \text{IC}_{50} \) = half-maximal inhibitory concentration (in terms of molar concentration), and \( NHA \) = non-hydrogen atom. The recommended LE value should be in the range of 0.3. The preferred LE value should be higher than 0.3. The LE values for selected drugs are represented in Table 4.

Ligand Lipophilic Efficiency (LLE) offers a way to determine the affinity of a drug with respect to its lipophilicity. LLE is defined as the difference between the potency and cLogP, as explained in the following equation:

\[
\text{LLE} = \text{pIC}_{50} - \text{cLogP}
\]

The challenge in drug discovery is to improve the activity while keeping lipophilicity constant. For this, LLE is considered an effective and practical tool of keeping lipophilicity under control to avoid any “molecular obesity” during the drug optimization process. An acceptable lead drug should have LLE value \( \geq 3 \), while LLE value \( \geq 5 \) is recommended for drug-like candidates.

As shown in Table 4, Azithromycin displayed good LLE value followed by Niclosamide. On the other hand, and among the mentioned drugs, Azithromycin showed the lowest LE. Although Doxycycline had low potency, it had the highest LLE value, suggesting that this drug requires further optimization studies.

| Rule of Five (ROS) | NHA | HBA | HBD | cLogP | Experimental Data |
|-------------------|-----|-----|-----|-------|-------------------|
| Azithromycin      | 749 | 52  | 14  | 5     | IC<sub>50</sub> (µM) | pIC<sub>50</sub> | LE | LLE |
| Niclosamide       | 327 | 21  | 4   | 2     | 0.32             | 6.49              | 0.17 | 4.05 |
| Nitazoxanide      | 307 | 21  | 7   | 1     | 0.16             | 6.79              | 0.44 | 3.84 |
| Celecoxib         | 381 | 26  | 4   | 1     | 2.12             | 1.29              | 5.89 | 0.30 | 3.77 |
| Piroxicam         | 331 | 23  | 5   | 2     | 4.01             | 13.02             | 4.89 | 0.26 | 0.88 |
| Doxycycline       | 444 | 32  | 9   | 6     | 3.1              | 5.21              | 5.09 | 0.30 | 1.99 |

NHA: non-hydrogen atom = heavy atom; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; ROS: rule of thumb to evaluate drug likeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would make it likely orally active; LE: Ligand efficiency; LLE: Ligand Lipophilic Efficiency; IC<sub>50</sub>: half maximal inhibitory concentration; pIC<sub>50</sub>: Negative log of the IC<sub>50</sub> value.

Celecoxib has the lowest LLE value. Piroxicam represented lipophilicity indices scores better than Celecoxib. These results suggest prescribing Piroxicam in combination with antibiotic in COVID-19 patients rather than Celecoxib. Regarding the rule of five values (Table 4), Azithromycin violates the rule of five as it has Mwt more than 500, and number of HBD and HBA more than five. Niclosamide, Nitazoxanide, Celecoxib, and Piroxicam obey the rule of five. Doxycycline showed violation in numbers of HBD and HBA. Azithromycin is eliminated in liver [21], it displayed low LE and violated the rule of five. These results indicate that patients with advanced stage of COVID-19 and compromised liver function may face problems with administration of Azithromycin [22,23].

2.5. Azithromycin Can Selectively Inhibit the Replication of SARS-CoV-2 Virus but Not MERS-CoV

To investigate whether the antiviral effect of the three FDA-approved drugs is common for other highly pathogenic coronaviruses or only selective against SARS-CoV-2, both SARS-CoV-2 and MERS-CoV viruses were treated with equal concentrations of the three drugs. Interestingly, Azithromycin showed a promising inhibitory activity against SARS-CoV-2 (viral inhibition is approximately 80% to 90%), compared to MERS-CoV (viral inhibition is approximately 20% to 30%) at
the lowest (5 µM) and highest (10 µM) concentrations tested, respectively. However, Niclosamide and Nitazoxanide are equally effective against SARS-CoV-2 and MERS-CoV (Figure 5a, b).

![Bar graph](image1)

**Figure 5.** Differential anti-SARS-CoV-2 and Anti-MERS-CoV activities for Azithromycin, Niclosamide, and Nitazoxanide. (a) Anti-SARS-CoV-2 activity for Azithromycin, Niclosamide, and Nitazoxanide, as measured by Plaque reduction assay. (b) Anti-MERS-CoV activity for Azithromycin, Niclosamide, and Nitazoxanide, as measured by Plaque reduction assay.

2.6. Docking Study with MERS-CoV Viral Proteins

2.6.1. Docking with the Main Protease

In order to examine the activity of these drugs against MERS-CoV virus, especially that Azithromycin displayed weak activity against MERS-CoV (Figure 5b), the docking protocol was employed here against the main protease of MERS-CoV (PDB ID: 4ylu [24]). Binding interaction was arranged as follow: Niclosamide with consensus score value 2, then Nitazoxanide with consensus score value 4, and finally, Azithromycin with consensus score value 6.

Regarding their binding mode and pose, both Niclosamide and Nitazoxanide represented overlay to each other inside the active site, with capability of Nitazoxanide to form HB with GLN:167A (Figure 6a). Both exhibited high similarity inside the receptor compared to Mpro of SARS-CoV-2 (Figure 3b). Additionally, they exhibited a high degree of pose similarity with standard co-crystallized ligand. The ligand participated in HB with the NH peptide of GLU:169A (Figure 6b). Azithromycin occupied the receptor with formation of HB with the carboxylic functionality of GLU:169A. In comparison to the co-crystallized ligand, the amino group of Azithromycin bared outside the inner grid of the receptor (Figure 6c).

Interestingly, Azithromycin was completely buried inside the inner grid of the main protease of SARS-CoV-2 (Supplementary Figure S5). As a result, the volume of drugs and volume of the receptor of the main protease for SARS-CoV-2 and MERS-CoV could participate in directing the potency.
2.6.2. Docking with the Spike Protein (PDB ID: 5x4r)

The standard co-crystallized ligand deposited in the receptor with formation of HB with GLU:249A [25] (Supplementary Figure S6). Drugs showed binding strength order as follows: Nitazoxanide, Niclosamide, and Azithromycin with consensus scores 0, 5, and 7, respectively. Both Niclosamide (HB with LEU:251A) and Nitazoxanide (two HBs with ASN:125A and LEU:251A) overlay each other with the ligand (Figure 7b). Azithromycin occupied the receptor with formation of HB with ASN:125A (Figure 7b).

Figure 6. Visual representation by VIDA for docking with the main protease of MERS-CoV (PDB ID: 4ylu). (a) Niclosamide (green color) and Nitazoxanide (grey color) overlay each other, (b) ligand (grey color), Niclosamide (green color), and Nitazoxanide (grey color with yellow sulfur atom color) inside the inner grid for validation, and (c) Azithromycin with amino outside the grid.
2.6.2. Docking with the Spike Protein (PDB ID: 5x4r)

The standard co-crystalized ligand deposited in the receptor with formation of HB with GLU:249A [25] (Supplementary Figure S6). Drugs showed binding strength order as follows: Nitazoxanide, Niclosamide, and Azithromycin with consensus scores 0, 5, and 7, respectively. Both Niclosamide (HB with LEU:251A) and Nitazoxanide (two HBs with ASN:125A and LEU:251A) overlay each other with the ligand (Figure 7b). Azithromycin occupied the receptor with formation of HB with ASN:125A (Figure 7b).

![Figure 6](Image)

![Figure 7](Image)

**Figure 7.** Visual representation by VIDA for docking with the main protease of MERS-CoV (PDB ID: 5x4r). (a) Azithromycin forms HB with ASN:125A, and (b) Niclosamide (grey color) and Nitazoxanide (green color) overlay each other.
3. Discussion

Drug repositioning represents a promising approach to recognize off-label indications for formerly approved drugs that are different from their conventional medical uses. This approach offers the advantage of minimizing the required time, cost, and efforts for drug discovery process and safety evaluation. Furthermore, it reduces the risk of the drugs to fail, particularly due to safety issues since the majority of drugs are repositioned after verifying their safety in preclinical and clinical studies [9,10]. At the same time, drug repositioning demands an extensive study concerning the drug profile and new targeted disease mechanisms.

COVID-19 is considered a critical threat to the public health, and what aggravated the situation is that there is no existing antiviral therapy that is clinically approved for the management of this disease. Hence, the drug repositioning approach can be utilized as an opportunity for rapid screening of potential therapeutic options against SARS-CoV-2.

The current study signified numerous novel outcomes to be used as guidance or recommendations during the implementation of the FDA-approved drugs in the treatment protocol. Our results revealed that among the investigated drugs, Niclosamide, Azithromycin, and Nitazoxanide depicted the most potent antiviral activities against SARS-CoV-2 in Vero-E6 cells with IC\textsubscript{50} values of 0.16, 0.32, and 1.29 µM, respectively. Regarding the mechanism of antiviral effect, the three examined drugs exhibited dual viral inhibition mechanisms. Both Azithromycin and Nitazoxanide exert their effects by virucidal action, while the antiviral effect of Niclosamide is mainly exerted through the inhibition of viral replication.

Additionally, the results of the in silico studies demonstrated strong binding affinity of the drugs to the viral main protease receptor in a descending order: Niclosamide, Nitazoxanide, and Azithromycin. On the other hand, the binding affinity of the tested drugs to the viral spike glycoprotein was in this descending order: Nitazoxanide, then Niclosamide, and Azithromycin. Furthermore, our results revealed that amongst all investigated drugs, Celecoxib showed the least LLE, thus the replacement of Celecoxib by Piroxicam in the treatment of COVID-19 patients is strongly suggested. Moreover, the administration of Azithromycin in advanced cases may cause problems to the patients as the drug violates the rule of five that is used to evaluate the drug-likeness. It is also noteworthy to mention that Azithromycin showed a selective inhibitory effect on SARS-CoV-2 but not on MERS-CoV, while Nitazoxanide and Niclosamide exhibited equal effects on both types of coronaviruses. These results are in accordance with the reported data in the literature that signified the broad antiviral activity spectrum of Nitazoxanide against various viruses [9]. In a recent study, Nitazoxanide has been reported to have in vitro antiviral activity against SARS-CoV-2 with IC\textsubscript{50} of 2.12 µM [26], which is in accordance with our findings but with higher value (1.29 µM). Hence, researchers have suggested that this drug may be beneficial as a therapy for COVID-19 [27] considering not only the antiviral effect of Nitazoxanide but also its favorable inhibitory action against pro-inflammatory cytokines as well as its bronchodilatory effect [9]. Similarly, Niclosamide was reported to have antiviral inhibitory effects against a wide range of viruses such as Japanese encephalitis virus, MERS-CoV, Zika virus, hepatitis C virus, Ebola virus, Chikungunya virus, and human rhinoviruses [28]. Azithromycin was reported to have antiviral activities against many viruses such as SARS-CoV-2 [29], Zika virus [30], and Ebola virus [31]; however, the reported IC\textsubscript{50} of Azithromycin against SARS-CoV-2 was 2.12 µM, which is higher than our results (0.32 µM) [29]. Herein, we propose Azithromycin, Niclosamide, and Nitazoxanide as novel and potent anti-SARS-CoV-2 drugs with potential therapeutic benefits in the treatment of COVID-19 patients. Besides, we provided preliminary data about FDA-approved drugs that could contribute in a dual mechanism to an anti-inflammatory response in patients with COVID-19 and partially hinder virus replication. We could show that Aspirin with anti-inflammatory, analgesic, antipyretic, and antithrombotic effects demonstrates antiviral activity against SARS-CoV-2. This finding is consistent with previous reports demonstrating that Aspirin has similar antiviral activity against different respiratory viruses such as human influenza viruses, rhinoviruses [32], human CoV-229E, and MERS-CoV in vitro [33]. The antiviral activity
of Aspirin is probably cell-mediated by inhibiting prostaglandin (PG) and thromboxane synthesis via irreversible inactivation of both cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2). Additionally, Aspirin modulates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, downregulates the expression and activity of the inducible nitric oxide synthase (iNOS), inhibits oxidative phosphorylation uncoupling, and increases permeability of the mitochondrial membrane [34]. Similarly, Piroxicam is a potent, nonsteroidal, antipyretic, and anti-inflammatory agent that showed antiviral activity against NRC-03-nhCoV. Piroxicam has also shown antiviral activity against Herpes Simplex Virus type 1 (HSV-1) in vitro via direct interaction of Piroxicam with the viral particle before adsorption [35].

Recently, Chlorpheniramine maleate, a competitive histamine H1 receptor antagonist, showed potent antiviral activity against a broad spectrum of influenza viruses with $IC_{50}$ of 3.56 and 11.84 µM. Accordingly, we showed that Chlorpheniramine maleate affected NRC-03-nhCoV at $IC_{50}$ value of 3.6 µM. More recently, Westover and his colleagues reported a strong virucidal effect against SARS-CoV-2 of a nasal spray containing Chlorpheniramine maleate [36].

In conclusion, this study highlighted two commonly prescribed categories of FDA-approved drugs with specific members of potent antiviral activities against SARS-CoV-2. Those drugs, listed in this study, with potent antiviral activity, still need investigations in clinical trials to determine their actual in vivo activity in the treatment of COVID-19. Therefore, self-medication of COVID-19 patients with these drugs without clinical studies may be a high-risk practice and is not recommended.

4. Materials and Methods

4.1. Virus, Cells and FDA-Approved Drugs

Vero-E6 cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% Fetal Bovine Serum (FBS) (Invitrogen) and 1% Penicillin/Streptomycin (pen/strep) antibiotic mixture at 37 °C, 5% CO₂. To generate virus stock, cells were distributed into tissue culture flasks 24 h prior to infection with hCoV-19/Egypt/NRC-3/2020 isolate at a multiplicity of infection (MOI) of 0.1 in infection medium (DMEM containing 2% FBS, 1% pen/strep, and 1% L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin. Two hours later, the infection medium containing virus inoculum was removed and replaced with fresh infection medium and incubated for three days. At the indicated time point, cell supernatant was collected and centrifuged for 5 min at 2500 rpm to remove small particulate cell debris. The supernatant was transferred to fresh 50 mL falcon tube, aliquoted, and titrated using the plaque infectivity assay.

The tested FDA-approved drugs, listed in Tables 1 and 2, were kindly granted by the Egyptian International Pharmaceutical Industries “EIPICO”, the Holding Company for Pharmaceuticals, Chemicals, and Medical Appliances “HoldiPharma”, and the National Organization for Drug Control and Research in Egypt.

4.2. MTT Cytotoxicity Assay

To assess the half maximal cytotoxic concentration (CC₅₀), stock solutions of the test compounds were prepared in 10% DMSO in ddH₂O and diluted further to the working solutions with DMEM. The cytotoxic activity of the extracts was tested in Vero-E6 cells by using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method with minor modifications. Briefly, the cells were seeded in 96-well plates (100 µL/well at a density of 3 x 10⁵ cells/mL) and incubated for 24 h at 37 °C in 5% CO₂. After 24 h, cells were treated with various concentrations of the tested compounds in triplicates. After 24 h, the supernatant was discarded, and cell monolayers were washed with sterile 1X phosphate buffer saline (PBS) 3 times, and MTT solution (20 µL of 5 mg/mL stock solution) was added to each well and incubated at 37 °C for 4 h followed by medium aspiration. In each well, the formed formazan crystals were dissolved with 200 µL of acidified isopropanol (0.04 M HCl in absolute isopropanol = 0.073 mL HCl in 50 mL isopropanol). Absorbance of formazan solutions
was measured at \( \lambda_{\text{max}} \) 540 nm with 620 nm as a reference wavelength using a multi-well plate reader. The percentage of cytotoxicity compared to the untreated cells was determined with the following equation.

The plot of % cytotoxicity versus sample concentration was used to calculate the concentration which exhibited 50% cytotoxicity (TC\(_{50}\)) [37]:

\[
\text{% cytotoxicity} = \left( \frac{\text{absorbance of cells without treatment} - \text{absorbance of cells with treatment}}{\text{absorbance of cells without treatment}} \right) \times 100
\]

4.3. Plaque Infectivity Assay

For the titration of hCoV-19/Egypt/NRC-03/2020 (NRC-03-nhCoV) (Accession Number on GSAID: EPI_ISL_430820), the plaque infectivity assay was carried out as previously described [38] with minor modifications. Briefly, the propagated virus was serially diluted 10-folds in medium without FBS. A volume of 100 \( \mu \)L of each individual virus dilution was mixed with 400 \( \mu \)L of infection medium and used to inoculate 80–90% confluent Vero-E6 cell monolayers. Control well was included in the same plate and was inoculated with 500 \( \mu \)L of serum-free medium. The plate was then incubated at 37 \( ^\circ \)C under 5% \( \text{CO}_2 \) for 1 h to allow virus adsorption and rocked every 15 min to ensure homogenous exposure of the cells to infection and avoid drying of cells. After 1 h, the virus inoculum was discarded and the cell monolayers were overlaid with 3 mL of DMEM plus 0.6% agarose containing 1 \( \mu \)g/mL of TPCK-treated trypsin, 10% FBS, and 1x pen/strep, and the appropriate concentration of the test drug. To allow the solidification of the agarose component of the overlay medium, the plate was left at room temperature (RT) for 10 min then incubated at 37 \( ^\circ \)C under 5% \( \text{CO}_2 \). After 72 h, 1 mL of fixation solution (10% formalin) was added to each well for 1 h for cell fixation and virus inactivation. The fixer was later discarded, and the plate wells were flushed with water and dried. For visualization of the plaques, 1 mL of the staining solution (0.1% crystal violet) was added to each well for 5 min, dye was discarded, and the plate wells were rinsed in water and dried. Viral plaques appeared as clear unstained spots (due to viral infection) in a violet (stained cells) background. The virus titer was calculated through the following equation:

\[
\text{Plaque forming unit (PFU) per mL} = \frac{\text{Number of plaques} \times \text{inoculated volume of the virus} \times \text{virus dilution}}{10^4}
\]

4.4. Plaque Reduction Assay

To assess the preliminary antiviral activity of the studied FDA-approved drugs, the plaque reduction assay [39] was carried out in a six-well plate, where Vero-E6 cells (1.2 \( \times \) 10\(^6\) cells) were cultivated for 24 h at 37 \( ^\circ \)C. The NRC-03-nhCoV virus was diluted to give 102 plaque forming units (PFU)/well and mixed with the safe concentration of the tested compounds and incubated for 1 h at 37 \( ^\circ \)C before being added to the cells. Growth medium was removed from the cell culture plates and the cells were inoculated with (100 \( \mu \)L/well) virus with the tested compounds. After 1 h of virus adsorption, 3 mL of DMEM supplemented with the overlay medium with the indicated concentrations of the tested compounds were added onto the cell monolayers. The plates were left to solidify and incubated at 37 \( ^\circ \)C until formation of viral plaques for 3 days. Cell fixing solution was added for 1 h, then plates were stained with 0.1% crystal violet in distilled water. Control wells were included, where untreated virus was incubated with Vero-E6 cells, and finally, plaques were counted and percentage reduction in plaques formation in comparison to control wells was recorded as following:

\[
\text{Percent of reduction} = \left( \frac{\text{untreated virus count} - \text{treated virus count}}{\text{untreated viral count}} \right) \times 100
\]

4.5. Inhibitory Concentration 50 (IC\(_{50}\)) Determination

In 96-well tissue culture plates, 2.4 \( \times \) 10\(^4\) Vero-E6 cells were distributed in each well and incubated overnight in a humidified 37 \( ^\circ \)C incubator under 5% \( \text{CO}_2 \) condition. The cell monolayers were then washed once with 1x PBS and subjected to virus adsorption for 1 h at room temperature (RT). The cell
monolayers were further overlaid with 50 µL of DMEM containing varying concentrations of the selected test compounds, Azithromycin, Niclosamide, and Nitazoxanide. Following incubation at 37 °C in 5% CO₂ incubator for 72 h, the cells were fixed with 100 µL of 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet in distilled water for 15 min at RT. The crystal violet dye was then dissolved using 100 µL absolute methanol per well and the optical density of the color measured at 570 nm using Anthos Zenyth 200 rt plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). The IC₅₀ of the compound is that required to reduce the virus-induced cytopathic effect (CPE) by 50%, relative to the virus control.

4.6. In Vitro Inhibition of Replication Efficiency at Different Virus Concentrations

Confluent Vero-E6 cells’ monolayers were infected with NRC-03-nhCoV in triplicate at MOI of 0.005 and 0.001 at 37 °C. The inocula were removed at 1 h post-infection (hpi), cell monolayers were washed with 1× PBS, and overlaid with infection media (1× DMEM supplemented with 1% Pen/Strep, 0.3% bovine serum albumin (BSA), and 2 µg/mL TPCK-treated trypsin). The cell culture supernatants were collected at 48 hpi. The virus titer was determined with plaque infectivity assay.

4.7. Mechanism of Action(s)

To investigate whether the tested drugs (Azithromycin, Niclosamide, and Nitazoxanide) with high selectivity index and potent activity against NRC-03-nhCoV affect (a) viral adsorption, (b) viral replication, or (c) viricidal effect, the plaque infectivity reduction assay was performed according to the following protocols.

4.7.1. Viral Adsorption Mechanism

The viral adsorption mechanism was assayed according to a protocol by Zhang and his colleagues [40] with minor modifications. Vero-E6 cells were cultivated in a 6-well plate (10⁵ cells/mL) for 24 h at 37 °C. Each tested drug was applied in 200 µL medium without supplements and co-incubated with the cells for 2 h at 4 °C. The inocula containing the non-absorbed drug were removed by washing cells three successive times with supplement-free medium. SARS-CoV-2 virus diluted to 10⁴ PFU/well was co-incubated with the pretreated cells for 1 h, and then 3 mL DMEM supplemented with 2% agarose were added. Plates were left to solidify and then incubated at 37 °C to allow the formation of viral plaques. The plaques were fixed and stained as described above to calculate the percentage reduction in plaque formation compared to control wells, which comprised untreated Vero-E6 cells directly infected with NRC-03-nhCoV.

4.7.2. Viral Replication Mechanism

The impact of tested drug on viral replication was determined as previously described [41]. Vero-E6 cells were cultivated in a 6-well plate (10⁵ cells/mL) for 24 h at 37 °C. Virus was inoculated directly to the cells and incubated for 1 h at 37 °C. The inocula containing the non-adsorbed viral particles were removed by washing cells three successive times with supplement-free medium. The test compound was added in varying concentrations to infected cells for another 1 h contact time. After removing the inocula containing the tested drug, 3 mL of DMEM supplemented with 2% agarose were added to the cell monolayer. Plates were left to solidify and incubated at 37 °C until the appearance of viral plaques. Cell monolayers were fixed in 10% formalin solution for 1 h and stained with crystal violet. Control wells contained Vero-E6 cells incubated with the virus. Plaques were counted and the percentage reduction in plaque formation was compared to the control wells.

4.7.3. Virucidal Mechanism

The virucidal mechanism was assayed following a previously described protocol [42]. In a 6-well plate, Vero-E6 cells were cultivated (10⁵ cells/mL) for 24 h at 37 °C and 200 µL of serum-free DMEM
containing SARS-CoV-2 was added to each sample with promising inhibition. After 1 h incubation, the mixture was diluted 10-fold three times using serum-free medium, which still allowed viral particles to grow on Vero-E6 cells. Next, 100 µL of each dilution were added to the Vero-E6 cell monolayer. After 1 h contact time, a DMEM overlayer was added to the cell monolayer. Plates were left to solidify and incubated at 37 °C to allow the formation of viral plaques. The plaques were fixed and stained as described above to calculate the percentage reduction in plaque formation. This value was compared to control wells comprising cells infected with virus and not pretreated with the tested material.

4.8. In Silico Analyses

4.8.1. Molecular Modeling

The X-ray crystal structure coordinates of SARS-CoV-2 main protease (Mpro) were retrieved from PDB (PDB ID: 6yef [17] and 6lu7 [43]) in addition to the retrieved receptor for S glycoprotein (PDB ID: 6vsb [18]) with their co-crystallized bound ligand α-ketoamide, N3, and ligand 1, respectively (Figure 2). The docking study was performed using OpenEye scientific software version 2.2.5 (SantaFe, NM, USA, http://www.eyesopen.com). For the validation of the docking study, the co-crystal-bound ligands were redocked. Both structures exhibited high similarity and overlaid each other, as reported in our previous work [16].

4.8.2. Physiochemical Parameter and Lipophilicity Calculations

Drugs’ parameters including cLogP were calculated according to their practical values as reported in CHEMBL, Drug Bank, and PubChem free access websites. Lipinski’s rule (Rule of five) was calculated by the free access website https://www.molsoft.com/servers.html.

4.9. Statistical Analyses

All experiments were performed in three biological repeats. Statistical tests and graphical data presentation were carried out using GraphPad Prism 5.01 software. Data are presented as the average of the means. The IC₅₀ and CC₅₀ curves represent the nonlinear fit of “Normalize” of “Transform” of the obtained data, their values were calculated using GraphPad prism as “best fit value”.

Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/13/12/443/s1, Figure S1: Half maximal cytotoxic concentration “CC₅₀” of the tested anti-microbial drugs in Vero-E6 cells. Various dilutions of the drugs were applied to the 90% confluent cell monolayers and assayed after 72 h with MTT assay. The half maximal cytotoxic concentrations “CC₅₀” were calculated using nonlinear regression analysis of GraphPad Prism software (version 5.01) by plotting log inhibitor versus normalized response (variable slope). Figure S2: Dose-response curves for anti-inflammatory, antipyretic, and anti-asthmatic FDA-approved drugs as determined by MTT assay. The half maximal cytotoxic concentrations “CC₅₀” were calculated using nonlinear regression analysis of GraphPad Prism software (version 5.01) by plotting log inhibitor versus normalized response (variable slope). Figure S3: Half maximal inhibitory concentration “IC₅₀” of the tested anti-microbial drugs against NRC-03-nCoV virus in Vero-E6 cells. Various dilutions of the drugs were applied to the 90% confluent cell monolayers and assayed after 72 h with crystal violet assay. The half maximal inhibitory concentrations “IC₅₀” were calculated using nonlinear regression analysis of GraphPad Prism software (version 5.01) by plotting log inhibitor versus normalized response (variable slope). Figure S4: Half maximal inhibitory concentration “IC₅₀” for anti-inflammatory, antipyretic, and anti-asthmatic FDA-approved drugs against NRC-03-nCoV virus in Vero-E6 cells. Various dilutions of the drugs were applied to the 90% confluent cell monolayers and assayed after 72 h with crystal violet assay. The half maximal inhibitory concentrations “IC₅₀” were calculated using nonlinear regression analysis of GraphPad Prism software (version 5.01) by plotting log inhibitor versus normalized response (variable slope). Figure S5: Azithromycin inside the grid receptor of Mpro of SARS-CoV-2. Figure S6: Co-crystalized ligand of MERS-CoV Spike protein ID: 5v4r” (a) Within the inner grid, and (b) Inside the receptor.

Author Contributions: Conceptualization, A.M., A.K., G.K. and M.A.A.; methodology, A.M., A.K., O.K., Y.M., M.S., M.R.G., N.M., S.H.M., M.G., A.E.T., A.E.K., M.N.K., M.E.S., D.B.M. and R.E.-S.; software, A.M., Y.A.M.M.E., A.A.R. and H.A.; validation, A.M., A.K., O.K. and Y.M.; formal analysis, A.M., A.K., G.K. and M.A.A.; investigation, A.M., Y.A.M.M.E., A.A.R. and H.A.; resources, A.M., D.B.M., G.K. and M.A.A.; data curation, A.M., A.K., G.K. and M.A.A.; writing—original draft preparation, A.M., A.K., D.B.M., G.K. and M.A.A.; writing—review and editing, A.M., G.K. and M.A.A.; visualization, A.M. and A.K.; supervision, A.M., A.K., G.K. and M.A.A.;
project administration, O.K. and Y.M.; funding acquisition, A.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the NRC under contract number MP120801 and by the Egyptian Academy of Scientific Research and Technology (ASRT) within the “Ideation Fund” program under contract number 7303. This research was also funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services (under contract HHSN272201400006C). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Acknowledgments:** We acknowledge OpenEye Scientific Software Incorporation for providing academic license of their software (To Y.A.M.E., Organic and Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City (USC), Egypt).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Peiris, J.S.M. Coronaviruses. In *Clinical Virology*, 4th ed.; Richman, D.D., Whitley, R.J., Hayden, F.J., Eds.; ASM Press: Washington, DC, USA, 2016; pp. 1243–1265. [CrossRef]
2. Mostafa, A.; Kandeil, A.; Shehata, M.; El Shesheny, R.; Samy, A.M.; Kayali, G.; Ali, M.A. Middle east respiratory syndrome coronavirus (mers-cov): State of the science. *Microorganisms* 2020, 8, 991. [CrossRef]
3. Wong, G.; Liu, W.; Liu, Y.; Zhou, B.; Bi, Y.; Gao, G.F. Mers, sars, and ebola: The role of super-spreaders in infectious disease. *Cell Host Microbe* 2015, 18, 398–401. [CrossRef]
4. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in saudi arabia. *N. Engl. J. Med.* 2012, 367, 1814–1820. [CrossRef]
5. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A novel coronavirus from patients with pneumonia in china. *N. Engl. J. Med.* 2020, 382, 727–733. [CrossRef]
6. Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, Japan, 2020. *Eurosurveillance* 2020, 25, 2000180. [CrossRef]
7. WHO. Who Coronavirus Disease (Covid-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 8 September 2020).
8. Chan, J.F.; Kok, K.H.; Zhu, Z.; Chu, H.; To, K.K.; Yuan, S.; Yuen, K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting wuhan. *Emerg. Microbes Infect.* 2020, 9, 221–236. [CrossRef]
9. Mahmoud, D.B.; Shitu, Z.; Mostafa, A. Drug repurposing of nitazoxanide: Can it be an effective therapy for covid-19? *J. Genet. Eng. Biotechnol.* 2020, 18, 35. [CrossRef]
10. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guiliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 2019, 18, 41–58.
11. Russell, B.; Moss, C.; Rigg, A.; Van Hemelrijck, M. Covid-19 and treatment with nsaid and corticosteroids: Should we be limiting their use in the clinical setting? *Ecamermedicalscience* 2020, 14, 1023. [CrossRef] [PubMed]
12. Little, P. Non-steroidal anti-inflammatory drugs and covid-19. *BMJ* 2020, 368, m1185. [CrossRef] [PubMed]
13. Giollo, A.; Adami, G.; Gatti, D.; Idolazzi, L.; Rossini, M. Coronavirus disease 19 (covid-19) and non-steroidal anti-inflammatory drugs (nsaid). *Ann. Rheum. Dis.* 2020. [CrossRef] [PubMed]
14. Cox, M.J.; Loman, N.; Bogaert, D.; O’Grady, J. Co-infections: Potentially lethal and unexplored in covid-19. *Lancet Microbe* 2020, 1, e11. [CrossRef]
15. Hsu, J. How covid-19 is accelerating the threat of antimicrobial resistance. *BMJ* 2020, 369, m1983. [CrossRef] [PubMed]
16. Allam, A.E.; Assaf, H.K.; Hassan, H.A.; Shimizu, K.; Elshaier, Y.A.M.M. An in silico perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of covid-19. *RSC Adv.* 2020, 10, 29983–29998. [CrossRef]
17. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of mpro from sars-cov-2 and discovery of its inhibitors. *Nature* 2020, 582, 289–293. [CrossRef]
18. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-em structure of the 2019-ncov spike in the prefusion conformation. *Science* **2020**, *367*, 1260–1263. [CrossRef]

19. Schultes, S.; de Graaf, C.; Haaksma, E.E.J.; de Esch, I.J.P.; Leurs, R.; Krämer, O. Ligand efficiency as a guide in fragment hit selection and optimization. *Drug Discov. Today Technol.* **2010**, *7*, e157–e162. [CrossRef]

20. Jabeen, I.; Pleban, K.; Rinner, U.; Chiba, P.; Ecker, G.F. Structure–activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter p-glycoprotein. *J. Med. Chem.* **2012**, *55*, 3261–3273. [CrossRef]

21. Singlas, E. Clinical pharmacokinetics of azithromycin. *Pathol. Biol.* **1995**, *43*, 505–511.

22. Norman, B.H. Drug induced liver injury (dili). Mechanisms and medicinal chemistry avoidance/mitigation strategies. *J. Med. Chem.* **2020**, *63*, 11397–11419. [CrossRef]

23. European Association for the Study of the Liver. Easl clinical practice guidelines: Drug-induced liver injury. *J. Hepatol.* **2019**, *70*, 1222–1261. [CrossRef]

24. Tomar, S.; Johnston, M.L.; St John, S.E.; Osswald, H.L.; Nyalapatla, P.R.; Paul, L.N.; Ghosh, A.K.; Denison, M.R.; Mesecar, A.D. Ligand-induced dimerization of middle east respiratory syndrome (mers) coronavirus nsp5 protease (3clpro): Implications for nsp5 regulation and the development of antivirals. *J. Biol. Chem.* **2015**, *290*, 19403–19422. [CrossRef] [PubMed]

25. Yuan, Y.; Cao, D.; Zhang, Y.; Ma, J.; Qi, J.; Wang, Q.; Lu, G.; Wu, Y.; Yan, J.; Shi, Y.; et al. Cryo-em structures of mers-cov and sars-cov spike glycoproteins reveal the dynamic receptor binding domains. *Nat. Commun.* **2017**, *8*, 15092. [CrossRef] [PubMed]

26. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro. *Cell Res.* **2020**, *30*, 269–271. [CrossRef] [PubMed]

27. Pepperrell, T.; Pilkington, V.; Owen, A.; Wang, J.; Hill, A.M. Review of safety and minimum pricing of nitazoxanide for potential treatment of covid-19. *J. Virus Erad.* **2020**, *6*, 52–60. [CrossRef]

28. Xu, J.; Shi, P.-Y.; Li, H.; Zhou, J. Broad spectrum antiviral agent niclosamide and its therapeutic potential. *ACS Infect. Dis.* **2020**, *6*, 909–915. [CrossRef]

29. Touret, F.; Gilles, M.; Barral, K.; Nougaïrède, A.; van Helden, J.; Decroly, E.; de Lamballerie, X.; Coutard, B. In vitro screening of a fda approved chemical library reveals potential inhibitors of sars-cov-2 replication. *Sci. Rep.* **2020**, *10*, 13093. [CrossRef]

30. Li, C.; Zu, S.; Deng, Y.Q.; Li, D.; Varvatiyar, K.; Quanquin, N.; Shang, J.; Sun, N.; Su, J.; Liu, Z.; et al. Azithromycin protects against zika virus infection by upregulating virus-induced type i and iii interferon responses. *Antimicrob. Agents Chemother.* **2019**, *63*. [CrossRef]

31. Kouznetsova, J.; Sun, W.; Martinez-Romero, C.; Tawa, G.; Shinn, P.; Chen, C.Z.; Schimmer, A.; Sanderson, P.; McKew, J.C.; Zheng, W.; et al. Identification of 53 compounds that block ebola virus-like particle entry via a repurposing screen of approved drugs. *Emerg. Microbes Infect.* **2014**, *3*, e84. [CrossRef]

32. Glattoar-Saalmüller, B.; Mair, K.H.; Saalmüller, A. Antiviral activity of aspirin against rna viruses of the respiratory tract-an in vitro study. *Influenza Respir. Viruses* **2017**, *11*, 85–92. [CrossRef]

33. Müller, C.; Karl, N.; Ziebuhr, J.; Pleschka, S. D-L-Lysine acetylsalicylate+ glycin impairs coronavirus replication. *J. Antivir. Antiretrovir.* **2016**, *8*, 142–150. [CrossRef]

34. Amin, A.R.; Attur, M.G.; Pillinger, M.; Abramson, S.B. The pleiotropic functions of aspirin: Mechanisms of action. *Cell. Mol. Life Sci.* **1999**, *56*, 305–312. [CrossRef] [PubMed]

35. Astani, A.; Albrecht, U.; Schnitzler, P. Piroxicam inhibits herpes simplex virus type 1 infection in vitro. *Die Pharm.* **2015**, *70*, 331–336.

36. Westover, J.B.; Ferrer, G.; Vazquez, H.; Bethencourt-Mirabal, A.; Go, C.C. In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2. *Cureus* **2020**, *12*, e10501. [PubMed]

37. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [CrossRef]

38. Payne, S. Methods to study viruses. *Viruses* **2017**, *37*, 52. [CrossRef]

39. Hayden, F.G.; Cote, K.M.; Douglas, R.G., Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. *Antimicrob. Agents Chemother.* **1980**, *17*, 865–870. [CrossRef]
40. Zhang, J.; Zhan, B.; Yao, X.; Gao, Y.; Song, J. Antiviral activity of tannin from the pericarp of punica granatum l. Against genital herpes virus in vitro. Zhongguo Zhong Yao Za Zhi 1995, 20, 556–558.

41. Kuo, Y.C.; Lin, L.C.; Tsai, W.J.; Chou, C.J.; Kung, S.H.; Ho, Y.H. Samarangenin b from limonium sinense suppresses herpes simplex virus type 1 replication in vero cells by regulation of viral macromolecular synthesis. Antimicrob. Agents Chemother. 2002, 46, 2854–2864. [CrossRef]

42. Schuhmacher, A.; Reichling, J.; Schnitzler, P. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro. Phytomedicine 2003, 10, 504–510. [CrossRef]

43. Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of sars-cov-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020, 368, 409–412. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).